|
515 Companies |
|
302 Products |
|
302 Products |
|
167 Mechanisms of Action |
|
1404 Trials |
|
125634 News |
|
| «12...15131514151515161517151815191520152115221523...15771578» |
- |||| ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Trial primary completion date, Surgery: EURAMOS-1: Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma (clinicaltrials.gov) - Nov 25, 2016
P3, N=1164, Active, not recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Oct 2013 --> Jan 2017
- || Tazverik (tazemetostat) / Ipsen
Enrollment change: A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma (clinicaltrials.gov) - Nov 25, 2016
P1, N=108, Recruiting, Sponsor: Epizyme, Inc.
Trial primary completion date: Oct 2013 --> Jan 2017 N=44 --> 108
- || Tibsovo (ivosidenib) / Servier
Enrollment closed, Metastases: Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation (clinicaltrials.gov) - Nov 25, 2016
P1, N=170, Active, not recruiting, Sponsor: Agios Pharmaceuticals, Inc.
N=44 --> 108 Recruiting --> Active, not recruiting
- | Votrient (pazopanib) / Novartis, BeiGene
Trial suspension, Metastases: Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer (clinicaltrials.gov) - Nov 25, 2016
P1, N=51, Suspended, Sponsor: Virginia Commonwealth University
Recruiting --> Active, not recruiting Recruiting --> Suspended
- Enrollment change, Trial withdrawal, MRI: Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas (clinicaltrials.gov) - Nov 23, 2016
P=N/A, N=0, Withdrawn, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Suspended N=49 --> 0 | Recruiting --> Withdrawn
- Kisqali (ribociclib) / Novartis
Enrollment closed, P2 data, Metastases: A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma (clinicaltrials.gov) - Nov 23, 2016
P2, N=30, Active, not recruiting, Sponsor: Hadassah Medical Organization
N=49 --> 0 | Recruiting --> Withdrawn Recruiting --> Active, not recruiting
- Sutent (sunitinib) / Pfizer
Phase classification, Trial primary completion date, Stroma, Metastases: A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor (clinicaltrials.gov) - Nov 23, 2016
P2, N=30, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2017 --> Aug 2017 | Phase classification: P1/2 --> P2
- everolimus / Generic mfg.
Trial suspension, Trial primary completion date: CHONRAD: A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas (clinicaltrials.gov) - Nov 22, 2016
P2, N=57, Suspended, Sponsor: Centre Leon Berard
Trial primary completion date: Dec 2017 --> Aug 2017 | Phase classification: P1/2 --> P2 Recruiting --> Suspended | Trial primary completion date: Aug 2016 --> Aug 2018
- || Oncophage (Heat Shock Protein Peptide Complex-96) / Agenus, Avastin (bevacizumab) / Roche
Trial primary completion date, Surgery: Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery (clinicaltrials.gov) - Nov 21, 2016
P2, N=165, Recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Suspended | Trial primary completion date: Aug 2016 --> Aug 2018 Trial primary completion date: Apr 2016 --> Jul 2017
- ||| buparlisib (AN2025) / Novartis, Adlai Nortye
Trial completion, Trial primary completion date, Combination therapy, Stroma: A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients (clinicaltrials.gov) - Nov 18, 2016
P1, N=60, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Apr 2016 --> Jul 2017 Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jul 2016
- New trial: microRNA Profiles Identification in Adeno Carcinoma Prostate Cancer (clinicaltrials.gov) - Nov 16, 2016
P=N/A, N=120, Not yet recruiting, Sponsor: Assuta Medical Center
- | Avastin (bevacizumab) / Roche
Enrollment change: Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Nov 16, 2016
P3, N=637, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jul 2016 N=978 --> 637
- Votrient (pazopanib) / Novartis, BeiGene
Trial primary completion date, Surgery: Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Nov 15, 2016
P=N/A, N=21, Active, not recruiting, Sponsor: University of Washington
N=978 --> 637 Trial primary completion date: Oct 2016 --> Jul 2016
- Fibromun (onfekafusp alfa) / Philogen
Trial primary completion date, Combination therapy, Metastases: L19TNF? in Combination With Doxorubicin in Patients With Advanced Solid Tumours (clinicaltrials.gov) - Nov 15, 2016
P1, N=28, Recruiting, Sponsor: Philogen S.p.A.
Trial primary completion date: Oct 2016 --> Jul 2016 Trial primary completion date: Nov 2015 --> Jun 2018
- dimethyl fumarate / Generic mfg., temozolomide / Generic mfg.
Enrollment closed, Enrollment change: Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - Nov 15, 2016
P1, N=12, Active, not recruiting, Sponsor: Virginia Commonwealth University
Trial primary completion date: Nov 2015 --> Jun 2018 Recruiting --> Active, not recruiting | N=23 --> 12
- || Lartruvo (olaratumab) / Eli Lilly
Trial primary completion date, Metastases: ANNOUNCE 2: A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Nov 14, 2016
P1b, N=196, Recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting | N=23 --> 12 Trial primary completion date: Jul 2019 --> Feb 2020
- Trial initiation date: A Platform of Patient Derived Xenografts (PDX) and 2D/3D Cell Cultures of Soft Tissue Sarcomas (STS) (clinicaltrials.gov) - Nov 14, 2016
P=N/A, N=25, Not yet recruiting, Sponsor: The Netherlands Cancer Institute
Trial primary completion date: Jul 2019 --> Feb 2020 Initiation date: Sep 2016 --> Jan 2017
- MV-NIS / Vyriad
New P1 trial: Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT (clinicaltrials.gov) - Nov 13, 2016
P1, N=24, Not yet recruiting, Sponsor: University of California, San Francisco
- bortezomib / Generic mfg., temozolomide / Generic mfg.
Trial primary completion date, Combination therapy: Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma (clinicaltrials.gov) - Nov 9, 2016
P2, N=25, Active, not recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Initiation date: Sep 2016 --> Jan 2017 Trial primary completion date: Oct 2016 --> Dec 2017
- Trial primary completion date: High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors (clinicaltrials.gov) - Nov 9, 2016
P=N/A, N=174, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Oct 2016 --> Dec 2017 Trial primary completion date: Oct 2016 --> Apr 2018
- | Trial initiation date: PRESOV: Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer (clinicaltrials.gov) - Nov 8, 2016
P2/3, N=160, Not yet recruiting, Sponsor: Assistance Publique - H
Trial primary completion date: Oct 2016 --> Apr 2018 Initiation date: Jul 2016 --> Nov 2016
- decitabine / Generic mfg., gemcitabine / Generic mfg.
New P1 trial, Metastases: Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma (clinicaltrials.gov) - Nov 8, 2016
P1b, N=36, Not yet recruiting, Sponsor: Laith Abushahin
- || letrozole / Generic mfg.
Trial primary completion date: Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma (clinicaltrials.gov) - Nov 7, 2016
P2, N=80, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Initiation date: Jul 2016 --> Nov 2016 Trial primary completion date: Dec 2017 --> Dec 2018
- Lynparza (olaparib) / Merck (MSD), AstraZeneca
Enrollment change, Metastases: Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma (clinicaltrials.gov) - Nov 7, 2016
P1, N=93, Recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Dec 2017 --> Dec 2018 N=34 --> 93
- Enrollment change: Whole Lung IMRT in Children and Adults With Synovial Sarcoma and Lung Metastases (clinicaltrials.gov) - Nov 4, 2016
P2, N=15, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
N=34 --> 93 N=10 --> 15
- ||| Ibrance (palbociclib) / Pfizer
Enrollment open, Combination therapy, Metastases: Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors (clinicaltrials.gov) - Nov 4, 2016
P1, N=90, Recruiting, Sponsor: Emory University
N=10 --> 15 Not yet recruiting --> Recruiting
- Ogsiveo (nirogacestat) / SpringWorks Therap
New trial, Metastases: Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov) - Nov 3, 2016
P=N/A, N=0, Temporarily Not Available, Sponsor: University of Colorado, Denver
- cyclophosphamide / Generic mfg., thalidomide / Generic mfg.
Trial primary completion date, Post-transplantation: Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors (clinicaltrials.gov) - Nov 3, 2016
P0, N=12, Recruiting, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2017 --> Feb 2018
- Zonalta (Z-endoxifen hydrochloride) / Jina Pharma, Intas
Trial primary completion date: Endoxifen in Adults With Hormone Receptor Positive Solid Tumors (clinicaltrials.gov) - Nov 3, 2016
P1, N=72, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Feb 2017 --> Feb 2018 Trial primary completion date: Oct 2016 --> Oct 2017
- carboplatin / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date: Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma (clinicaltrials.gov) - Nov 3, 2016
P2, N=65, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Oct 2016 --> Oct 2017 Trial primary completion date: Oct 2016 --> Oct 2017
- Cometriq (cabozantinib capsule) / Exelixis, Ipsen, Cabometyx (cabozantinib tablet) / Exelixis
Enrollment change: Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma (clinicaltrials.gov) - Nov 3, 2016
P2, N=60, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2016 --> Oct 2017 N=50 --> 60
- ganitumab (AMG 479) / Takeda, ImmunityBio
Phase classification, Combination therapy, Metastases: QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors (clinicaltrials.gov) - Nov 3, 2016
P1b/2, N=89, Terminated, Sponsor: NantCell, Inc.
N=50 --> 60 Phase classification: P1/2 --> P1b/2
- Trial completion, Enrollment change: Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer (clinicaltrials.gov) - Nov 3, 2016
P=N/A, N=15, Completed, Sponsor: University of Wisconsin, Madison
Phase classification: P1/2 --> P1b/2 Active, not recruiting --> Completed | N=30 --> 15
- SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax, Roswell Park Comprehensive Cancer Center
Enrollment closed, Trial primary completion date: Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma (clinicaltrials.gov) - Nov 2, 2016
P1, N=9, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed | N=30 --> 15 Completed --> Active, not recruiting | Trial primary completion date: May 2014 --> May 2017
- Cometriq (cabozantinib capsule) / Exelixis, Ipsen, Cabometyx (cabozantinib tablet) / Exelixis
Enrollment change, Trial suspension: Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma (clinicaltrials.gov) - Nov 2, 2016
P2, N=50, Suspended, Sponsor: National Cancer Institute (NCI)
Completed --> Active, not recruiting | Trial primary completion date: May 2014 --> May 2017 N=90 --> 50 | Recruiting --> Suspended
- Trial completion: Study of Physical and Psychosocial Rehabilitation Needs of Patients After Diagnosis and Treatment of Upper Gastrointestinal Cancer or Gynecological Cancer (clinicaltrials.gov) - Nov 1, 2016
P=N/A, N=33, Completed, Sponsor: Royal Marsden NHS Foundation Trust
N=90 --> 50 | Recruiting --> Suspended Recruiting --> Completed
- Trial completion, Trial primary completion date, Adverse events: Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer (clinicaltrials.gov) - Nov 1, 2016
P=N/A, N=177, Completed, Sponsor: Royal Marsden NHS Foundation Trust
Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Apr 2012 --> Dec 2012
- ganitumab (AMG 479) / Takeda, ImmunityBio
Metastases: AEWS1221: Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (clinicaltrials.gov) - Nov 1, 2016
P2, N=140, Suspended, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | Trial primary completion date: Apr 2012 --> Dec 2012 Recruiting --> Suspended
- | efatutazone (CS-7017) / Daiichi Sankyo
Enrollment open, Surgery: Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Oct 31, 2016
P2, N=36, Recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Suspended Suspended --> Recruiting
- | Injectafer (ferric carboxymaltose) / Zeria Pharma, Vifor, Daiichi Sankyo
New P2 trial, Stroma: Efficacy of Ferric Carboxymaltose in Gastrointestinal Stromal Tumor (GIST) Patients With Iron Deficiency Anemia (IDA) Receiving Systemic Therapy (clinicaltrials.gov) - Oct 31, 2016
P2, N=50, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- Trial completion: Collecting Tumor Samples From Patients With Gynecological Tumors (clinicaltrials.gov) - Oct 28, 2016
P=N/A, N=275, Completed, Sponsor: Gynecologic Oncology Group
Suspended --> Recruiting Recruiting --> Completed
- |||| Ibrance (palbociclib) / Pfizer
Trial completion, Trial primary completion date, Metastases: PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma (clinicaltrials.gov) - Oct 27, 2016
P2, N=90, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Oct 2016
- ThermoDox (lyso-thermosensitive liposomal doxorubicin) / Imunon
Enrollment open, Trial initiation date: A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors (clinicaltrials.gov) - Oct 27, 2016
P1, N=34, Recruiting, Sponsor: AeRang Kim
Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Oct 2016 Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Oct 2016
- pegylated liposomal doxorubicin / Generic mfg.
Trial initiation date, Trial primary completion date: HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors (clinicaltrials.gov) - Oct 26, 2016
P1, N=14, Not yet recruiting, Sponsor: Theodore Laetsch
Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Oct 2016 Initiation date: Apr 2016 --> Dec 2016 | Trial primary completion date: Sep 2017 --> Dec 2018
- | albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
New P2 trial, Combination therapy: Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma (clinicaltrials.gov) - Oct 26, 2016
P2, N=72, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- imatinib / Generic mfg.
Trial primary completion date: Study to Evaluate Imatinib in Desmoid Tumors (clinicaltrials.gov) - Oct 25, 2016
P2, N=40, Active, not recruiting, Sponsor: Heidelberg University
Initiation date: Apr 2016 --> Dec 2016 | Trial primary completion date: Sep 2017 --> Dec 2018 Trial primary completion date: Jun 2016 --> Dec 2016
- Trial completion, Trial primary completion date: p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors (clinicaltrials.gov) - Oct 25, 2016
P1, N=18, Completed, Sponsor: Pediatric Brain Tumor Consortium
Trial primary completion date: Jun 2016 --> Dec 2016 Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Apr 2015
- Lartruvo (olaratumab) / Eli Lilly
Enrollment open, Combination therapy, Monotherapy: A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma (clinicaltrials.gov) - Oct 25, 2016
P1b, N=40, Recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Apr 2015 Not yet recruiting --> Recruiting
- | zotiraciclib (TG02) / Cothera Biosci
New P2 trial: Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma (clinicaltrials.gov) - Oct 25, 2016
P2, N=152, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | plerixafor / Generic mfg.
Enrollment change: A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone (clinicaltrials.gov) - Oct 21, 2016
P1/2, N=30, Active, not recruiting, Sponsor: Genzyme, a Sanofi Company
Not yet recruiting --> Recruiting N=46 --> 30